GLPwatch
Bipolar disorder
Investigational / off-label
Last updated 2026-05-28 15:46 UTCSome studies have examined psychiatric adverse events associated with GLP-1 drugs, including reports related to bipolar disorder, but no sources provide direct evidence of GLP-1 drugs treating or worsening bipolar disorder.
AI summary of the sources below.
Approved GLP-1 drugs (0)
No GLP-1 drug is FDA-approved for bipolar disorder in our data. Any research below reflects investigational or off-label study.
Research (31)
- Psychotropic Drug-Related Weight Gain and Its Treatment.
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System.
- The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder.
- Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder.
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
- Liraglutide for psychiatric disorders: clinical evidence and challenges.
- Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
- Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery.
- A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: Target engagement and rationale for the development in mental disorders.
- Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.
- The effect of glucagon-like Peptide-1 receptor agonists on measures of suicidality: A systematic review.
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review.
- Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study.
- A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state <i>via</i> GSK-3β pathway.
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study.
- Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.
- Liraglutide attenuates clozapine-induced mitochondrial dysfunction and improves energy metabolism in the brain of rats.
- Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review.
- Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Binge Eating Disorder: A Narrative Review.
- Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
- Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.
- Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.
- GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis.
- Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.
- The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study.
- Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.
- [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]
Common questions
- Which GLP-1 drugs are FDA-approved for Bipolar disorder?
- No GLP-1 drug is currently FDA-approved for bipolar disorder; any use would be off-label or investigational.
- Is there research on GLP-1 drugs for Bipolar disorder?
- GLPwatch tracks 31 research papers on GLP-1 drugs and bipolar disorder. This research is investigational and does not imply FDA approval.